Peptic Ulcer Disease (PUD) represents a significant worldwide public health burden, with a high rate of morbidity and economic cost. However, in recent years, advancements in diagnostic techniques, pharmacotherapy, and endoscopic interventions have greatly improved the management of this condition.
Diagnosis of PUD has been revolutionized with the advent of non-invasive tests such as urea breath test and stool antigen test for Helicobacter pylori infection. These tests have high sensitivity and specificity, and are more patient-friendly than traditional invasive methods.
Advancements in pharmacotherapy have led to a significant reduction in ulcer recurrence and complications. Proton pump inhibitors (PPIs) remain the cornerstone of PUD management, providing rapid symptom relief and promoting ulcer healing. Novel PPIs with longer half-life and improved acid suppression are currently under investigation. Moreover, the introduction of quadruple therapy, including bismuth, has improved the eradication rates of H. pylori, the main causative agent of PUD.
Endoscopic interventions have transformed the management of PUD complications. Endoscopic hemostasis using clips, band ligation, and thermal devices has become the first-line treatment for bleeding peptic ulcers. In refractory cases, endoscopic ultrasound-guided angiotherapy is emerging as a promising technique.
The landscape of PUD management has significantly changed over the past few years, with advancements in diagnostic methods, pharmacological treatments, and endoscopic interventions. These developments have improved patient outcomes, reduced hospitalization rates, and decreased healthcare costs. However, further research is needed to refine these strategies and develop new therapeutic options to overcome the challenges associated with PUD management.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation